Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

Company Overview

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use. Neurocrine also commercializes Orilissa® (elagolix), a once-daily oral therapy for endometriosis, and Oriahnn® (elagolix with estradiol and norethindrone acetate) for the management of heavy menstrual bleeding associated with uterine fibroids. In addition, Neurocrine has licensed opicapone, a catechol-O-methyltransferase inhibitor for Parkinson’s disease “OFF” episodes, in partnership with BIAL.

Beyond its approved products, Neurocrine maintains a diversified pipeline targeting conditions such as essential tremor, amyotrophic lateral sclerosis and Cushing’s syndrome. The company conducts clinical trials in North America, Europe and Asia, and leverages strategic partnerships to expand its global reach. This collaborative approach has enabled external commercialization agreements and regulatory submissions in multiple jurisdictions.

Leadership at Neurocrine is headed by President and Chief Executive Officer Kevin C. Gorman, under whose tenure the company has secured key regulatory approvals and forged licensing deals with major pharmaceutical firms. Over the years, Neurocrine has grown from a research‐focused startup into a commercial biotech organization with a mission to develop innovative therapies for challenging neurological and endocrine diseases.

Key Stats

• Today's Range: $155.44 to $158.63
• 50-Day Range: $126.32 to $161.32
• 52-Week Range: $117.59 to $162.39
• Volume: 758,737 shs
• Average Volume: 1.33 million shs
• Market Capitalization: $15.76 billion
• P/E Ratio: 24.14
• Dividend Yield: N/A
• Price Target: $185.90
• Consensus Rating: Moderate Buy

Neurocrine Biosciences Stock Analysis - MarketRank™

Neurocrine Biosciences scored higher than 76% of companies evaluated by MarketBeat, and ranked 157th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Neurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 17 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

Neurocrine Biosciences has a consensus price target of $185.90, representing about 18.6% upside from its current price of $156.70.

Amount of Analyst Coverage

Neurocrine Biosciences has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 31.56%

Earnings Growth

Earnings for Neurocrine Biosciences are expected to grow by 31.56% in the coming year, from $7.16 to $9.42 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neurocrine Biosciences is 24.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neurocrine Biosciences is 24.14, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.01.

Price to Earnings Growth Ratio

Neurocrine Biosciences has a PEG Ratio of 1.18. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Neurocrine Biosciences has a P/B Ratio of 4.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.25% of the float of Neurocrine Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Neurocrine Biosciences has a short interest ratio ("days to cover") of 5.15.

Change versus previous month

Short interest in Neurocrine Biosciences has recently increased by 6.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neurocrine Biosciences does not currently pay a dividend.

Dividend Growth

Neurocrine Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.51

News Sentiment

Neurocrine Biosciences has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Neurocrine Biosciences this week, compared to 7 articles on an average week.

Search Interest

Only 8 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.

MarketBeat Follows

11 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,779,769.00 in company stock.

Percentage Held by Insiders

4.60% of the stock of Neurocrine Biosciences is held by insiders.

Percentage Held by Institutions

92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/11/2026
• Today: 5/25/2026
• Next Earnings (Estimated): 7/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NBIX
• CIK: 914475
• Web: www.neurocrine.com
• Phone: (858) 617-7600
• Fax: 858-617-7602
• Employees: 2,000
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Neurocrine Biosciences: $185.90
• High Price Target: $246.00
• Low Price Target: $140.00
• Potential Upside/Downside: +18.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.49
• Trailing P/E Ratio: 24.14
• Forward P/E Ratio: 21.89
• P/E Growth: 1.18
• Net Income: $478.60 million
• Net Margins: 21.55%
• Pretax Margin: 30.22%
• Return on Equity: 19.79%
• Return on Assets: 13.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.93
• Quick Ratio: 2.85

Sales & Book Value

• Annual Sales: $3.10 billion
• Price / Sales: 5.08
• Cash Flow: $5.01 per share
• Price / Cash Flow: 31.26
• Book Value: $33.89 per share
• Price / Book: 4.62

Miscellaneous

• Outstanding Shares: 100,550,000
• Free Float: 95,925,000
• Market Cap: $15.76 billion
• Optionable: Optionable
• Beta: 0.34